Articles related to BLADDER CANCER

Older adults with advanced or metastatic urothelial carcinoma treated with enfortumab vedotin experienced substantially higher rates of severe toxicity and treatment discontinuation than younger patients, while survival outcomes appeared similar across age groups.

In patients with cisplatin-eligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab improved event-free and overall survival compared with standard neoadjuvant gemcitabine-cisplatin chemotherapy in the phase 3 KEYNOTE-B15 trial.

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

“We’re lucky to have found it at this stage where I could say the word cure, because I don’t use that word lightly as a cancer doctor.” – Dr. Janet Kukreja, the Director of Urologic Oncology at the CU Cancer Center/UC Health University of Colorado Hospital

“Controlling cancer is, of course, the goal, but there must also be a greater emphasis on life after treatment.”

Company leadership demands FDA explanation for approving identical treatment in patients with CIS while refusing filing for those without CIS, despite same trial data showing comparable clinical benefits and safety profiles.